In vivo 'purging' of residual disease in CLL with Campath-1H

British Journal of Haematology

Volumn 97, Issue 3, 1997, Pages 669-672

  Dyer, M J S ^a   Kelsey, S M ^b   Mackay, H J ^a   Emmett, E ^a   Thornton, P ^a   Hale, G ^c   Waldmann, H ^c   Newland, A C ^b   Catovsky, D ^a,d  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Campath 1H; CLL

Indexed keywords

ALEMTUZUMAB; FLUDARABINE; PENTOSTATIN;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER REGRESSION; CELL INFILTRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MINIMAL RESIDUAL DISEASE; PRIORITY JOURNAL;

EID: 0030964964     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.1062924.x     Document Type: Article

References (10)

1. Dyer, M.J.S., Hale, G., Hayhoe, F.G. & Waldmann, H. (1989) Effects of Campath-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype. Blood, 73, 1431-1439.
2. Dyer, M.J.S., Hale, G., Marcus, R.E. & Waldmann, H. (1990) Remission induction in patients with lymphoid malignancies using unconjugated Campath-1H monoclonal antibodies. Leukemia and Lymphoma, 2, 179-193.
3. Grossbard, M.L., Press, O.W., Appelbaum, F.R., Bernstein, I.D. & Nadler, L.M. (1992) Monoclonal antibody-based therapies of leukemia and lymphoma. Blood, 80, 865-878.
4. Hale, G., Dyer, M.J.S., Clark, M.R., Phillips, J.M., Marcus, R., Reichmann, L., Winter, G. & Waldmann, H. (1988) Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody Campath-1H. Lancet, ii, 1394-1399.
5. Juliusson, G., Oscier, D.G., Fitchett, M., Ross, F.M., Stockdill, G., Mackie, M.J., Parker, A.C., Castoldi, G.L., Cuneo, A., Knuutila, S., Elonen, E. & Gahrton, G. (1990) Prognostic subgroups in B cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. New England Journal of Medicine, 323, 720-724.
6. Keating, M.J., O'Brien, P., Robertson, L.E., Kantarjian, K., Dimopoulous, M., McLaughlin, P., Cabanillas, F., Gregoire, V., Li, Y.Y. & Gandhi, V. (1994) The expanding role of fludarabine in hematological malignancies. Leukemia and Lymphoma, 14, 11-66.
7. Rabinowe, S.N., Soiffer, R.J., Gribben, J.G., Daley, H., Freedman, A.S., Daley, J., Pesek, K., Neuberg, D., Pinkus, G. & Leavitt, P.R. (1993) Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. Blood, 82, 1366-1376.
8. Riethmuller, G., Schneider-Gadicke, E., Schlimlok, G., Schmiegel, W., Raab, R., Hoffken, K., Gruber, R., Pichlmaier, H., Hirche, H., German Cancer Aid 17-1A Study Group (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes C colorectal carcinoma. Lancet, 343, 1177-1183.
9. Saven, A., Lemon, R.H., Kosty, M., Beutler, E. & Piro, L.D. (1995) 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Journal of Clinical Oncology, 13, 570-574.
10. Vuillier, F., Claisse, J.F., Vandenvelde, C., Travade, P., Magnac, C., Chevret, S., Desablens, B., Binet, J.L. & Dighiero, G. (1992) Evaluation of residual disease in B-cell chronic lymphocytic leukemia patients in clinical and bone marrow remission using CD5/CD19 markers and PCR study of gene rearrangements. Leukemia, 7, 195-204.